Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
Combination effects of docetaxel (DOC) and doxorubicin (DOX) were investigated in prostate cancer cells (PC3 and DU145). Combination indices (CIs) were determined using the unified theory in various concentrations and mixing ratios (synergy: CI<0.9, additivity: 0.9<CI<1.1, and antagonism: C...
Main Authors: | Eleftheria Tsakalozou, Allison M. Eckman, Younsoo Bae |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Biochemistry Research International |
Online Access: | http://dx.doi.org/10.1155/2012/832059 |
Similar Items
-
Docetaxel (Tautax) in the treatment of hormone-refractory prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-02-01) -
Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
by: Victoria J Sinibaldi
Published: (2008-01-01) -
Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
by: Fabien Calcagno, et al.
Published: (2013-01-01) -
Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
by: Fabien Calcagno, et al.
Published: (2012-12-01) -
Clinical Study of Docetaxel, Prednisone and Bevacizunab in the Treatment of Hormone Refractory Prostate Cancer
by: Theodore D. Koreckij, et al.
Published: (2015-06-01)